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InductOs® to the standard care in CLBP is a cost saving strat-
egy in the Spanish setting.
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OBJECTIVES: Intracerebral hemorrhage (ICH) is among the
most costly and debilitating forms of stroke. Results from a
recent Phase IIb clinical trial demonstrate that administration of
recombinant activated factor VII (rFVIIa) reduces ICH mortal-
ity and improves functional outcome. The objective is to examine
the health plan budget impact of introducing rFVIIa as a novel
treatment for ICH. METHODS: A decision-analytic model was
adapted to estimate the budget impact of introducing rFVIIa (40,
80, or 160 μg per kilogram) for treatment of ICH, from a US
managed care perspective. The patient population was similar to
that of the Phase IIb clinical trial. Model structure and inputs
were obtained from published literature, clinical trial data,
managed care claims databases, and expert opinion. All costs are
presented in 2005 US dollars. Costs and outcomes were dis-
counted at 3 percent annually. Univariate sensitivity analyses
were conducted to assess model robustness. RESULTS: Assum-
ing a health plan of 1,000,000 members and an initial 30%
uptake of rFVIIa, the annual health plan cost is expected to
increase by between $38,868 and $279,057, or between $0.003
and $0.023 per-member per-month, depending on dose of rFVIIa
used. Assuming use of rFVIIa 80 μg/kg dose and an absolute 5%
increase in uptake each year (i.e., 55% patients receiving rFVIIa
80 μg/kg 5 years post introduction), the change in a health plan’s
annual cost is expected to be −$65,778 (cost savings) compared
to the current year’s budget at 5 years after rFVIIa introduc-
tion. CONCLUSIONS: Treating eligible patients with rFVIIa
improves survival and functional outcome. Impact to a health
plan’s budget is modest in the ﬁrst year after introduction to
market. In addition, due to expected improvements in health out-
comes, a decrease in budget impact may be observed using
rFVIIa 80 μg/kg as early as 3 years post introduction.
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OBJECTIVES: To evaluate the relation between post-stroke
physical disability and place of residence (home vs long-term 
care facility), and, secondarily, between disability and other 
economic, quality of life and caregiver burden outcomes.
METHODS: Randomly selected Erlangen Registry ischemic
stroke patients, 18 years of age or older, still alive at least 90
days post stroke and willing to attend a study visit were admin-
istered a 30-day retrospective resource use questionnaire, the
EQ-5D, the Stroke Impact Scale (SIS-16), Modiﬁed Rankin Scale
(mRS), and Barthel Index; caregivers reported resource use and
hours of informal care. Stroke history was obtained from 
registry records. Multivariate logistic and linear regressions 
were used to examine the associations. Preliminary results are
reported for the ﬁrst 200 of the planned 360 subjects. RESULTS:
At a mean time post stroke of 4 years (min 0.26—max 11.88
years), 14.5%, 25%, 25%, 13%, 7.5%, and 15% of subjects
(49.5% male; mean age 74.3 years) had mRS scores of 0, 1, 2,
3, 4 and 5, respectively. At the study visit, 72% of patients were
residing at home, and 28% were residing in a long-term care
facility. The probability of residing in long-term care was signif-
icantly higher in patients with severe disability (mRS = 3,4,5) vs
mild/moderate disability (mRS = 0,1,2) (adjusted for age, sex,
and time since index stroke; OR = 14.8, p < 0.0001). Over the
previous 7 days, 96% of caregivers of severely disabled subjects
cared for at home vs 50% of caregivers of the mildly/moderately
disabled patients at home reported ≥1 hour of informal care 
(p < 0.001); mean informal care time received by patients with
severe disability was 26.6 hours; patients with mild/moderate
disability received 6.6 hours (p < 0.001). CONCLUSIONS:
Results suggest post-stroke impairment remains an important
determinant of place of residence and caregiver burden well
beyond the acute care period, outcomes which translate into sig-
niﬁcant additional costs.
PST3
RESOURCE UTILIZATION AND COSTS OF STROKES IN A
THIRD LEVEL HOSPITAL IN MÉXICO
Carbajal A1, Soto H2, Salazar J3, Zanela O4,Talavera J5
1Hospital de Especialidades, IMSS, Delegacion Cuauhtemoc, Mexico
D.F, Mexico, 2Universidad del Estado de Mexico,Toluca, Edo de
Mexico, Mexico, 3Hospital de Especialidades, IMSS, Delegación
Cuauhtemoc, Mexico D.F, Mexico, 4Universidad del Estado De
México,Toluca, Estado de Mexico, Mexico, 5Hospital de
especialidades, IMSS, Delegacion Cuauhtemoc, México D.F, Mexico
OBJECTIVE: To estimate resource utilization and economic
costs of a stroke in Specialty Hospital (SH) of XXI Century
National Medical Center (CMNSXXI, in Spanish). METHODS:
Data from stroke-diagnosed patients who received medical assis-
tance in SH between 2003–05 were retrospectively collected,
with the following inclusion criteria: 1) assistance with <24
hours after ﬁrst symptoms, 2) CAT or magnetic resonance-con-
ﬁrmed stroke, and 3) >45 years old. The Barthel index was used
to assess clinical status. Costs were estimated from the hospital
perspective using a bottom-up approach, and only direct medical
costs were estimated (hospitalization, treatment, laboratory
tests, specialist visit, surgery). Clinical data and resource utiliza-
tion were obtained from individual clinical. The unitary costs
used are those ofﬁcially published by Mexican Social Security
institute (IMSS). A 3% discount rate was used, and prices were
adjusted as to February 2006. Results are shown either as mean-
standard (SD) or median-range and multivariate analysis test
were applied. Sensitivity analyses included variation of the
resource use frequency assumptions, percent complicated
patients and cost inputs. RESULTS: 88 patients were included,
Male 63.64%, age 55.59 (18.68), Mortality were 19.32%. More
resources were utilized for complicated patients compared to
non-complicated in CAT (1.68 vrs 1.12, p = 0.006), thorax Rx
(3.19 vrs 1.44, p = 0.002), angiography (0.41 vrs 0.19, p = 0.04)
and days of hospitalization (15 vrs 8.4, p = 0.0019). Total stroke
costs were MXN$103,493 ($101,783.2),median = $66,789.15,
range $20,158–$501,685.2). 62.36% of total costs were due to
hospitalization. Per-patient costs for a complicated and non-
complicated stroke were $151,308 and $69,926.03, respectively
(p < 0.0015). Sensitivity analysis highlighted the modelxs sensi-
tivity to the percent complicated patients and cost inputs. CON-
